- Home
- CELC vs WLY Comparison
CELC vs WLY Comparison
Compare CELC & WLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- WLY
- Stock Information
- Founded
- CELC 2011
- WLY 1807
- Country
- CELC United States
- WLY United States
- Employees
- CELC N/A
- WLY N/A
- Industry
- CELC Medical Specialities
- WLY Books
- Sector
- CELC Health Care
- WLY Consumer Discretionary
- Exchange
- CELC Nasdaq
- WLY Nasdaq
- Market Cap
- CELC 2.3B
- WLY 2.2B
- IPO Year
- CELC 2017
- WLY N/A
- Fundamental
- Price
- CELC $50.51
- WLY $39.97
- Analyst Decision
- CELC Strong Buy
- WLY
- Analyst Count
- CELC 6
- WLY 0
- Target Price
- CELC $63.00
- WLY N/A
- AVG Volume (30 Days)
- CELC 1.0M
- WLY 346.8K
- Earning Date
- CELC 11-13-2025
- WLY 09-04-2025
- Dividend Yield
- CELC N/A
- WLY 3.55%
- EPS Growth
- CELC N/A
- WLY N/A
- EPS
- CELC N/A
- WLY 1.78
- Revenue
- CELC N/A
- WLY $1,670,600,000.00
- Revenue This Year
- CELC N/A
- WLY $1.45
- Revenue Next Year
- CELC N/A
- WLY $2.70
- P/E Ratio
- CELC N/A
- WLY $22.45
- Revenue Growth
- CELC N/A
- WLY N/A
- 52 Week Low
- CELC $7.58
- WLY $36.10
- 52 Week High
- CELC $63.06
- WLY $53.96
- Technical
- Relative Strength Index (RSI)
- CELC 49.45
- WLY 46.60
- Support Level
- CELC $44.42
- WLY $39.49
- Resistance Level
- CELC $52.76
- WLY $40.72
- Average True Range (ATR)
- CELC 3.10
- WLY 0.89
- MACD
- CELC -1.11
- WLY -0.11
- Stochastic Oscillator
- CELC 51.39
- WLY 18.91
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About WLY John Wiley & Sons Inc.
John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.